vs

Side-by-side financial comparison of Ivanhoe Electric Inc. (IE) and InMed Pharmaceuticals Inc. (INM). Click either name above to swap in a different company.

Ivanhoe Electric Inc. is the larger business by last-quarter revenue ($896.0K vs $820.2K, roughly 1.1× InMed Pharmaceuticals Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -4500.4%, a 4253.2% gap on every dollar of revenue. On growth, InMed Pharmaceuticals Inc. posted the faster year-over-year revenue change (-26.2% vs -32.7%). Over the past eight quarters, Ivanhoe Electric Inc.'s revenue compounded faster (57.8% CAGR vs -16.4%).

Ivanhoe Electric Inc. is a critical minerals exploration and development firm focused on metals for global electrification. It targets high-grade copper, gold, silver and strategic deposits, with primary North American operations, supplying raw materials to renewable energy, EV and power grid infrastructure supply chains worldwide.

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

IE vs INM — Head-to-Head

Bigger by revenue
IE
IE
1.1× larger
IE
$896.0K
$820.2K
INM
Growing faster (revenue YoY)
INM
INM
+6.5% gap
INM
-26.2%
-32.7%
IE
Higher net margin
INM
INM
4253.2% more per $
INM
-247.3%
-4500.4%
IE
Faster 2-yr revenue CAGR
IE
IE
Annualised
IE
57.8%
-16.4%
INM

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
IE
IE
INM
INM
Revenue
$896.0K
$820.2K
Net Profit
$-40.3M
$-2.0M
Gross Margin
69.5%
22.5%
Operating Margin
-4167.7%
-247.3%
Net Margin
-4500.4%
-247.3%
Revenue YoY
-32.7%
-26.2%
Net Profit YoY
-318.3%
21.2%
EPS (diluted)
$0.24
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IE
IE
INM
INM
Q4 25
$896.0K
$820.2K
Q3 25
$545.0K
$1.1M
Q2 25
$1.1M
$1.3M
Q1 25
$735.0K
$1.3M
Q4 24
$1.3M
$1.1M
Q3 24
$671.0K
$1.3M
Q2 24
$538.0K
$1.3M
Q1 24
$360.0K
$1.2M
Net Profit
IE
IE
INM
INM
Q4 25
$-40.3M
$-2.0M
Q3 25
$-17.5M
$-1.7M
Q2 25
$-23.9M
$-1.8M
Q1 25
$-34.1M
$-2.1M
Q4 24
$18.5M
$-2.6M
Q3 24
$-43.2M
$-1.7M
Q2 24
$-46.8M
$-1.9M
Q1 24
$-60.1M
$-1.7M
Gross Margin
IE
IE
INM
INM
Q4 25
69.5%
22.5%
Q3 25
51.2%
36.0%
Q2 25
72.5%
44.2%
Q1 25
60.1%
13.9%
Q4 24
64.7%
41.5%
Q3 24
61.8%
39.0%
Q2 24
64.3%
36.3%
Q1 24
72.2%
24.7%
Operating Margin
IE
IE
INM
INM
Q4 25
-4167.7%
-247.3%
Q3 25
-4328.3%
-154.2%
Q2 25
-2400.3%
-137.1%
Q1 25
-3674.0%
-168.1%
Q4 24
-2229.4%
-231.6%
Q3 24
-6233.8%
-132.7%
Q2 24
-9023.4%
-150.5%
Q1 24
-15800.3%
-146.9%
Net Margin
IE
IE
INM
INM
Q4 25
-4500.4%
-247.3%
Q3 25
-3214.9%
-154.2%
Q2 25
-2233.2%
-137.1%
Q1 25
-4645.0%
-168.1%
Q4 24
1386.6%
-231.6%
Q3 24
-6443.5%
-132.7%
Q2 24
-8695.7%
-151.0%
Q1 24
-16693.1%
-146.9%
EPS (diluted)
IE
IE
INM
INM
Q4 25
$0.24
$-0.51
Q3 25
$0.13
$-0.44
Q2 25
$0.18
$-0.07
Q1 25
$0.24
$-1.94
Q4 24
$-0.14
$-3.64
Q3 24
$0.36
$-2.71
Q2 24
$0.39
$2.39
Q1 24
$0.46
$-3.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IE
IE
INM
INM
Cash + ST InvestmentsLiquidity on hand
$173.3M
$7.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.1M
$9.6M
Total Assets
$483.3M
$11.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IE
IE
INM
INM
Q4 25
$173.3M
$7.0M
Q3 25
$69.5M
$9.4M
Q2 25
$88.0M
$11.1M
Q1 25
$98.2M
$4.7M
Q4 24
$41.0M
$3.5M
Q3 24
$81.1M
$5.6M
Q2 24
$133.8M
$6.6M
Q1 24
$179.4M
Stockholders' Equity
IE
IE
INM
INM
Q4 25
$416.1M
$9.6M
Q3 25
$280.1M
$11.6M
Q2 25
$293.3M
$13.4M
Q1 25
$307.0M
$7.0M
Q4 24
$268.6M
$6.2M
Q3 24
$250.1M
$8.4M
Q2 24
$289.2M
$9.2M
Q1 24
$331.5M
$11.1M
Total Assets
IE
IE
INM
INM
Q4 25
$483.3M
$11.2M
Q3 25
$386.2M
$13.4M
Q2 25
$400.5M
$15.6M
Q1 25
$414.4M
$9.3M
Q4 24
$374.9M
$8.5M
Q3 24
$375.4M
$10.5M
Q2 24
$416.3M
$11.8M
Q1 24
$461.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IE
IE
INM
INM
Operating Cash FlowLast quarter
$-25.7M
$-2.4M
Free Cash FlowOCF − Capex
$-25.7M
FCF MarginFCF / Revenue
-2872.8%
Capex IntensityCapex / Revenue
4.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-90.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IE
IE
INM
INM
Q4 25
$-25.7M
$-2.4M
Q3 25
$-27.7M
$-1.6M
Q2 25
$-20.0M
$-1.8M
Q1 25
$-15.8M
$-1.7M
Q4 24
$-30.7M
$-2.5M
Q3 24
$-36.9M
$-1.8M
Q2 24
$-44.5M
$-1.0M
Q1 24
$-50.0M
$-1.9M
Free Cash Flow
IE
IE
INM
INM
Q4 25
$-25.7M
Q3 25
$-27.8M
Q2 25
$-21.3M
Q1 25
$-15.8M
Q4 24
$-32.4M
Q3 24
$-36.9M
Q2 24
$-45.0M
Q1 24
$-50.6M
$-1.9M
FCF Margin
IE
IE
INM
INM
Q4 25
-2872.8%
Q3 25
-5103.9%
Q2 25
-1990.1%
Q1 25
-2146.5%
Q4 24
-2432.4%
Q3 24
-5506.6%
Q2 24
-8372.9%
Q1 24
-14064.2%
-165.0%
Capex Intensity
IE
IE
INM
INM
Q4 25
4.1%
Q3 25
16.9%
Q2 25
117.6%
Q1 25
0.3%
Q4 24
127.3%
Q3 24
8.8%
Q2 24
93.7%
Q1 24
186.7%
0.0%
Cash Conversion
IE
IE
INM
INM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-1.66×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons